Aβ immunotherapy: Lessons learned for potential treatment of Alzheimer's disease

Neurodegenerative Diseases

Volumn 2, Issue 5, 2006, Pages 255-260

  Schenk, Dale B ^a   Seubert, Peter ^a   Grundman, Michael ^a   Black, Ron ^b  

^a ELAN PHARMACEUTICALS   (United States)

^b PFIZER INC   (United States)

Author keywords

A immunotherapy; Alzheimer's disease

Indexed keywords

ADJUVANT; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-16]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-5]; AMYLOID BETA PROTEIN[25-35]; AMYLOID BETA PROTEIN[3-6]; AMYLOID BETA PROTEIN[3-7]; IMMUNOGLOBULIN F(AB) FRAGMENT; QS 21; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BLEEDING; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MENINGOENCEPHALITIS; MULTIPLE DRUG DOSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; UNITED STATES; UNSPECIFIED SIDE EFFECT; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; CLINICAL TRIALS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; VACCINATION;

EID: 33744471433     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000090365     Document Type: Review

References (36)

1. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
2. Higgins GA, Jacobsen H: Transgenic mouse models of Alzheimer's disease: phenotype and application. Behav Pharmacol 2003;14:419-438.
3. Selkoe DJ, Schenk D: Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545-584.
4. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
5. 42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710-713.
6. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al: Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995;373:523-527.
7. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
8. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D: Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982.
9. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW: Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-985 (erratum in: Nature 2001; 412:660).
10. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T: Peripherally administered antibodies against amyloid-β peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-919.
11. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT: Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001;7:369-372.
12. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT: Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J Neurosci 2002;22:7873-7878.
13. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D: Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004;1:24.
14. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D: Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 2003;23:3745-3751.
15. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-8855.
16. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB: Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid-β. J Neurosci 2005;25:629-636.
17. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M: Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 2002;298:1379.
18. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM: Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-457.
19. Holtzman DM, Bales KR, Paul SM, DeMattos RB: Aβ immunization and anti-Aβ antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv Drug Deliv Rev 2002;54:1603-1613.
20. (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 2005;130:667-684.
21. Klein WL, Krafft GA, Finch CE: Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 2001;24:219-224.
22. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid-β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-539.
23. Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, Games D: Aβ immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 2005;25:9096-9101.
24. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FRT: Alzheimer's disease Aβ vaccine reduces central nervous system Aβ levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004;165:283-297.
25. 42 (AN1792) in patients with AD. Neurology 2005;64:94-101.
26. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003;9:448-452.
27. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D: Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005;64:129-131.
28. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F: Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol 2004;14:11-20.
29. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M: Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563-1572.
30. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562.
31. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM: Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547-554.
32. 42 immunization. Neurology 2003;61:46-54.
33. Kalback W, Watson MD, Kokjohn TA, Kuo YM, Weiss N, Luehrs DC, Lopez J, Brune D, Sisodia SS, Staufenbiel M, Emmerling M, Roher AE: APP transgenic mice Tg2576 accumulate Aβ peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 2002;41:922-928.
34. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE: Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 2001;276:12991-12998.
35. 42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies. Ann Neurol 2005;58:430-435.
36. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM: Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43:321-332.